Pharmaceutical Technology's In the Lab eNewsletter
Advanced HDX-MS and native MS techniques can be used to improve the identification of potentially successful biologic drugs and take the risk out of CMC and clinical designs.
Jennifer S. Chadwick
Advertisement
Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
Articles by Jennifer S. Chadwick
Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
PharmTech AI Pulse Check: AI Policies Become Regulators' Inspection Yardstick
5